PRTC

PureTech Announces Publication of Research from Collaborators Demonstrating PureTech’s Glyph™ Platform Enhances Oral Absorption of Buprenorphine (a Clinically-Validated Opioid Replacement Therapy)

Retrieved on: 
화요일, 4월 12, 2022
Biotechnology, Health, Science, Pharmaceutical, Research, Company, Private Securities Litigation Reform Act, Cancer, Pharmacy, Synthetic, Journal, PRTC, BUP, Therapy, U.S. FDA, Control, Multimedia, Fat, Patient, Liver, Research, SEC, Frontiers Media, Risk, Environment, Platform supply vessel, Monash University, Monash Institute of Medical Research, University of Melbourne, Pain management, Chem, Allopregnanolone, Lymphatic system, Immune system, Technology, Biology, Twitter, LSE, Brain, Chemistry, Degenerative disease, Journal of Controlled Release, Prodrug, BIG, Annual report, FDA, PureTech Health, Buprenorphine, Axis, Pharmaceutical industry, Trevaskis, Glyph, Pharmacology, Frontiers

View the full release here: https://www.businesswire.com/news/home/20220411005986/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220411005986/en/
    PureTech announced the publication of preclinical proof-of-concept showing up to 20-fold oral bioavailability enhancement by the Glyph platform of buprenorphine, a clinically-validated opioid replacement therapy.
  • Results from this study further amplify the breadth of the Glyph delivery technology and its ability to use new chemistry and molecules for versatile applications.
  • The Glyph technology generates novel orally dosed prodrugs by reversibly linking small molecule drugs to dietary fat molecules.
  • PureTechs LYT-300 is the first therapeutic candidate generated by the Glyph technology platform to enter the clinic.

PureTech Health: Notice of Results

Retrieved on: 
목요일, 4월 7, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Company, Private Securities Litigation Reform Act, Cancer, PRTC, Therapy, U.S. FDA, Annual report, ESG, Research, SEC, Risk, Environment, Biology, Twitter, LSE, Brain, Degenerative disease, BIG, FDA, PureTech Health, Axis, Pharmaceutical industry

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company") plans to publish its annual report and financial results on Tuesday, April 26, 2022 at 2:00 AM EDT / 7:00 AM BST.

Key Points: 
  • PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company") plans to publish its annual report and financial results on Tuesday, April 26, 2022 at 2:00 AM EDT / 7:00 AM BST.
  • The report will include the Companys financial results for the year ended December 31, 2021 and its cash balance for the first quarter ended March 31, 2022.
  • PureTech also plans to provide an overview of progress across its Wholly Owned Pipeline and Founded Entities in addition to the Companys approach to environmental, social and governance (ESG) practices, along with other business and strategy progress and updates.
  • A presentation and conference call to discuss the results will take place at 9:00 AM EDT / 2:00 PM BST on the day of publication, and a webcast of the presentation will be available on the Company's website at https://investors.puretechhealth.com/events-presentations .

PureTech Founded Entity Akili Appoints Game Industry Veteran Behind Bejeweled, Plants vs. Zombies as Chief Product Officer

Retrieved on: 
목요일, 3월 17, 2022
Science, Other Science, Biotechnology, Research, General Health, Health, Clinical Trials, Other Health, Private Securities Litigation Reform Act, Risk, PopCap Games, Register, Research, SEC, Environment, Medicine, CEO, Suite, Vii, SCS, Technology, Twitter, Securities Act of 1933, Tripura Merger Agreement, Nasdaq, LSE, Annual report, Proxy, U.S. FDA, Plant, Sale, Xi, Industry, Biology, Brain, Cancer, PRTC, Therapy, Form, Forward-looking statement, Multimedia, Social, Failure, Name, ALL, Prospectus, Electronic Arts, Magic, FDA, Patient, Registration statement, Axis, IP, Adoption, Microsoft, Company, Bejeweled Blitz, Government budget balance, Lists of video games, 100,000, Glu Mobile, XV, General manager, Communication, Xbox Live Arcade, Entrepreneurship, THE, Mergers and acquisitions, COVID-19, Degenerative disease, BIG, PureTech Health, Acquisition, Management, Video game, Security (finance), Risk management, Yolo Akili, Taunting, Akili, PureTech Health, AKILI, PURETECH HEALTH

View the full release here: https://www.businesswire.com/news/home/20220317005363/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220317005363/en/
    PureTech Founded Entity, Akili, announced the appointment of Jon David as Chief Product Officer.
  • The full text of the announcement from Akili is as follows:
    Game Industry Veteran Behind Bejeweled, Plants vs. Zombies Joins Akili as Chief Product Officer
    BOSTON, Mass.
  • March 17, 2022 Akili Interactive (Akili or the Company), a leading digital medicine company developing cognitive treatments through game-changing technologies, today announced the appointment of Jon David as Chief Product Officer.
  • Im looking forward to bringing even more joy and magic to the Akili product experience as we grow, said Jon David, Chief Product Officer at Akili.

PureTech Founded Entity Gelesis® Releases Preliminary National Launch Results for Plenity®: Record-Breaking Levels of Prescriptions and Online Traffic

Retrieved on: 
수요일, 3월 16, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, PRTC, Time, Absorption, Chief commercial officer, Flatulence, Xi, Risk, Nature, Financial result, Cellulose, CEO, New, Twitter, SEC, Allergy, Defecation, Private Securities Litigation Reform Act, Partnership, Human, Functional constipation, Forward-looking statement, COVID, LSE, U.S. FDA, NAFLD, Research, BIG, Growth, Diarrhea, NYSE, Abdomen, Gelatin, Citric acid, Gel, Patient, Health care, Pain scale, GLS, Therapy, Adoption, PureTech Health, Brain, Cancer, HCP, HCPS, Degenerative disease, Liver, Axis, Hearing, Ix, Non-alcoholic fatty liver disease, NASH, Annual report, Failure, FDA, Food, Type 2 diabetes, Pharming, Use, Environment, Awareness, 100,000, Company, Incidence, COVID 19, Biology, Prescription, Pharmaceutical industry, Health insurance, Risk management, Dietary supplement, Nitenpyram, Hydrogel, Gelesis, PureTech Health, GELESIS, PURETECH HEALTH

Gelesis anticipates that its 2022 net product revenue will be approximately $58 million in its first year of full launch, reaffirming guidance the company issued earlier this year.

Key Points: 
  • Gelesis anticipates that its 2022 net product revenue will be approximately $58 million in its first year of full launch, reaffirming guidance the company issued earlier this year.
  • Gelesis acquired approximately 4,700 new Plenity members per week within the first three weeks of the campaign.
  • Gelesis exclusive telehealth partner, Ro, responded to growing patient demand when it placed $40 million in pre-orders for Plenity last year.
  • Gelesis assumes no obligation and does not intend to update or revise the results provided in this press release.

Vedanta Biosciences to Present at Chardan’s 2022 Metagenomics and Microbiome Medicines Summit

Retrieved on: 
수요일, 2월 23, 2022
Oncology, Health, Infectious Diseases, General Health, Clinical Trials, Pharmaceutical, Biotechnology, PRTC, Immune system, Inflammatory Bowel Diseases, Texas Tech University College of Agricultural Sciences & Natural Resources, Food allergy, Term, Bacteria, Metagenomics, List of life sciences, PureTech Health, LSE, Cell, Research, Pharmaceutical industry, Nature, Science

Vedanta Biosciences , a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that Bernat Olle, Ph.D., chief executive officer of Vedanta Biosciences, will participate in a panel and present at the virtual Chardan Metagenomics and Microbiome Medicines Summit on Tuesday, March 1, 2022.

Key Points: 
  • Vedanta Biosciences , a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that Bernat Olle, Ph.D., chief executive officer of Vedanta Biosciences, will participate in a panel and present at the virtual Chardan Metagenomics and Microbiome Medicines Summit on Tuesday, March 1, 2022.
  • Panel Title: Great Debate - Is the Term Microbiome Drug Development Pass?
  • Vedanta Biosciences is leading the development of a potential new category of oral therapies based on defined consortia of bacteria isolated from the human microbiome and grown from pure clonal cell banks.
  • Vedanta Biosciences controls a foundational portfolio of more than 40 patents and has built what it believes to be the worlds biggest library of bacteria derived from the human microbiome.

PureTech Founded Entity Akili Interactive Announces Filing of Registration Statement on S-4 in Connection with its Proposed Business Combination with Social Capital Suvretta Holdings Corp. I

Retrieved on: 
화요일, 2월 15, 2022
Health, Technology, Other Technology, Other Health, General Health, Clinical Trials, Biotechnology, Adoption, LSE, Prospectus, XV, Private Securities Litigation Reform Act, Therapy, Technology, Suite, U.S. Securities and Exchange Commission, Government budget balance, Acquisition, U.S. FDA, Entrepreneurship, COVID-19, PALO, Mergers and acquisitions, Company, PRTC, Tripura Merger Agreement, SEC, Xi, Registration statement, Securities Act of 1933, Vii, SCS, Twitter, Degenerative disease, Sale, Research, 100,000, Industry, Connection, Social capital, ALL, Risk, Brain, Capitalism, Nasdaq, THE, Register, PureTech Health, Name, Cancer, Communication, Medicine, Form, Business architecture, Forward-looking statement, Annual report, Environment, Proxy, Biology, FDA, Axis, Failure, BIG, Online gambling, Audit, Security (finance), Property management, Risk management, Yolo Akili, Akili, Social Capital, Social Capital Suvretta Holdings Corp I, PureTech Health, AKILI, SOCIAL CAPITAL, SOCIAL CAPITAL SUVRETTA HOLDINGS CORP I, PURETECH HEALTH

The full text of the announcement from Akili is as follows:

Key Points: 
  • The full text of the announcement from Akili is as follows:
    Akili Interactive Announces Filing of Registration Statement on S-4 in Connection with its Proposed Business Combination with Social Capital Suvretta Holdings Corp.
  • and PALO ALTO, Calif. February 14, 2022 Akili Interactive (Akili or the Company), a leading digital medicine company developing cognitive treatments through game-changing technologies, announced that Social Capital Suvretta Holdings Corp.
  • I (SCS) (Nasdaq: DNAA) has filed with the U.S. Securities and Exchange Commission (SEC) a registration statement on Form S-4 (the Registration Statement), which contains a preliminary proxy statement/prospectus, in connection with the previously announced proposed business combination with Akili.
  • While the Registration Statement has not yet become effective and the information contained therein is subject to change, it provides important information about Akili and the proposed business combination with SCS.

PureTech to Present at the SVB Leerink 11th Annual Global Healthcare Conference

Retrieved on: 
목요일, 2월 10, 2022
Biotechnology, Health, Clinical Trials, Private Securities Litigation Reform Act, Multimedia, Axis, Conference, LSE, Research, Company, Twitter, PureTech Health, BIG, Annual report, SVB, U.S. FDA, FDA, Degenerative disease, Brain, SEC, Therapy, Environment, PRTC, Cancer, Biology, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20220210005227/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220210005227/en/
    PureTechs Bharatt Chowrira, Ph.D., J.D., President and Chief Business, Legal & Operating Officer, and Julie Krop, M.D., Chief Medical Officer, will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on Thursday, February 17, 2022, at 10:00am EST.
  • This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
  • All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those related to our upcoming presentation at the SVB Leerink Global Healthcare Conference and our future prospects, developments and strategies.
  • These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future.

PureTech to Present at 40th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
금요일, 1월 7, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, PRTC, U.S. FDA, Therapy, Research, Company, Environment, Cancer, Daphne, Conference, Twitter, LSE, Annual report, Private Securities Litigation Reform Act, Axis, Degenerative disease, SEC, PureTech Health, FDA, Biology, Brain, Multimedia, BIG, Pharmaceutical industry

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced that Daphne Zohar, Founder and Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 7:30am EST.

Key Points: 
  • PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced that Daphne Zohar, Founder and Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 7:30am EST.
  • View the full release here: https://www.businesswire.com/news/home/20220107005054/en/
    Daphne Zohar, Founder and Chief Executive Officer at PureTech, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 7:30am EST.
  • All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those related to our upcoming presentation at the 40th Annual J.P. Morgan Healthcare Conference and our future prospects, developments and strategies.
  • These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future.

PureTech Presents Preclinical Proof-of-Concept Data for LYT-300 (Oral Allopregnanolone) as Potential Treatment for Neurological and Neuropsychological Conditions

Retrieved on: 
수요일, 12월 8, 2021
Oncology, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Monash University, Anxiety, Twitter, Environment, Synthetic, Company, Research, SEC, LSE, Technology, Therapy, Annual general meeting, University of Melbourne, Platform supply vessel, PRTC, Immune system, Monash Institute of Medical Research, Safety, Allopregnanolone, Control, Private Securities Litigation Reform Act, GABAA, BIG, Cancer, Brain, Axis, Liver, Journal, Lymphatic system, Fat, PK, Epilepsy, American College, Depression, Epileptic Disorders, Sleep, Multimedia, Trial of the century, Pharmacy, FDA, PureTech Health, Essential tremor, Biology, Degenerative disease, U.S. FDA, Annual report, Prodrug, Pharmaceutical industry

Synthetic oral analogs of allopregnanolone have had variable clinical success, and comparable activity with natural allopregnanolone remains to be established.

Key Points: 
  • Synthetic oral analogs of allopregnanolone have had variable clinical success, and comparable activity with natural allopregnanolone remains to be established.
  • The data presented at ACNP showed that systemic exposure of natural allopregnanolone was achieved after oral administration of LYT-300 in multiple preclinical models of increasing complexity.
  • LYT-300 is a clinical therapeutic candidate that is in development as a potential treatment for a range of neurological and neuropsychological conditions.
  • Allopregnanolone is a positive allosteric modulator of -aminobutyric-acid type A (GABAA) receptors and has been shown to regulate mood and other neurological conditions.

PureTech Advances Wholly-Owned Candidate LYT-300 (Oral Allopregnanolone) into Clinical Study for Potential Treatment of Neurological and Neuropsychological Conditions

Retrieved on: 
화요일, 12월 7, 2021
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Sleep, Monash University, Anxiety, Twitter, Environment, Synthetic, Company, Lists of diseases, Research, SEC, LSE, Technology, Therapy, Pharmacokinetics, University of Melbourne, Platform supply vessel, PRTC, Immune system, Monash Institute of Medical Research, Allopregnanolone, Safety, Control, GABAA, BIG, Cancer, Brain, Axis, Private Securities Litigation Reform Act, Liver, Food, Journal, Lymphatic system, Fat, PK, Epilepsy, Depression, Epileptic Disorders, Multimedia, Trial of the century, Pharmacy, FDA, PureTech Health, Essential tremor, Biology, Degenerative disease, U.S. FDA, Annual report, Prodrug, Pharmaceutical industry

LYT-300 is designed to unlock the validated biology of allopregnanolone to potentially offer a new, oral treatment option for a range of conditions where there is significant patient need.

Key Points: 
  • LYT-300 is designed to unlock the validated biology of allopregnanolone to potentially offer a new, oral treatment option for a range of conditions where there is significant patient need.
  • Allopregnanolone is a powerful, natural regulator of mood disorders and other neurological conditions, but its therapeutic development has been limited by its poor oral bioavailability.
  • LYT-300 is a clinical therapeutic candidate that is in development as a potential treatment for a range of neurological and neuropsychological conditions.
  • Allopregnanolone is a positive allosteric modulator of -aminobutyric-acid type A (GABAA) receptors and has been shown to regulate mood and other neurological conditions.